Late-Stage Deals: Phase III and Beyond
July 2006
Late-Stage Deals: Phase III and Beyond
The Third Edition of PharmaVentures Business Review
Watch the whole program
Late-Stage Deals: Phase III and Beyond
In July's edition of the PharmaVentures Business Review we turn our attention to late-stage deal making, looking at some of the trends that PharmaVentures business analysts have been observing in the industry. In our exclusive face-to-face interview, we talk to Bruce Carter, CEO of ZymoGenetics, about its corporate strategy and drug development programmes, and we have the usual round-up of key deals and transactions that have taken place in the last month.
To learn more about the major deals and transactions from the previous month’s industry activity, you should view PharmaDeals Intelligence bank, a comprehensive and global source of deals information. With financial information, news alerts and legal agreements, this searchable resource, which is compiled by analysts and consultants, is an essential deal making tool.
- Novartis' collaboration with Cytopia for the development of new autoimmune therapies
- Genelabs' antihepatitis C virus therapy out-licensing deal with Novartis
- Novartis' US$569 M acquisition of the UK biopharmaceutical company Neutec Pharma
- Novartis' US$552.5 M licensing deal with Human Genome Sciences for antihepatitis C virus therapy
- Intercell's deal with Novartis for the rights to its Japanese encephalitis virus vaccine
- Pfizer's sale of its Consumer Healthcare division to Johnson & Johnson for US$16.6 B
Watch this segment
The Month in Review
With a focus on Novartis' recent deal making activity, this month we cover the following deals:
To learn more about the major deals and transactions from the previous month’s industry activity, you should view PharmaDeals Intelligence bank, a comprehensive and global source of deals information. With financial information, news alerts and legal agreements, this searchable resource, which is compiled by analysts and consultants, is an essential deal making tool.
- Novartis' collaboration with Cytopia for the development of new autoimmune therapies
- Genelabs' antihepatitis C virus therapy out-licensing deal with Novartis
- Novartis' US$569 M acquisition of the UK biopharmaceutical company Neutec Pharma
- Novartis' US$552.5 M licensing deal with Human Genome Sciences for antihepatitis C virus therapy
- Intercell's deal with Novartis for the rights to its Japanese encephalitis virus vaccine
- Pfizer's sale of its Consumer Healthcare division to Johnson & Johnson for US$16.6 B
Watch this segment
The Business Report
In the Business Report this month, we investigate the trends in deal making for products that have reached Phase III or later in the development process. Using data sourced from PharmaVentures' proprietary deal information resource, PharmaDeals® Agreements, we assess both the overall numbers and types of deals that have been made over the last 6 years, as well as taking a closer look at the most frequent late-stage deal types: marketing, licensing and manufacturing.
Watch this segment
Face-to-Face
Fintan Walton, CEO of PharmaVentures, talks exclusively to Bruce Carter, President and CEO of ZymoGenetics, a company that celebrated its 25th anniversary on 22 June 2006. Bruce discusses a number of aspects of ZymoGenetics' operations, including its relationship with previous owners Novo Nordisk, its alliance with Serono and its drug development model. Bruce also shares his views and advice on biotech acquisitions and the key characteristics of a successful biotech CEO.
Extra this month - Exclusive Interview
Jim Smith, CEO Genelabs Technologies, talks to PharmaVentures Business Review about the company's recent licensing deal with Novartis.
